Within the
biotechnology market,
BioNTech has secured an exceptional deal with
Bristol Myers Squibb (BMS), totaling up to $11.1 billion. This
partnership is aimed at infiltrating the sector of
cancer immunotherapy, focusing on the development of an
experimental cancer drug. A key player in the COVID-19 vaccine drive, the German company's shares have seen a bump as this fresh collaboration brings much promise. The drug in question, a
bispecific cancer drug, places BMS in direct competition with big pharma corporations like Merck and Pfizer. BioNTech continues its ascend in the biotech industry with this deal, bouncing back from a clinical hold on its
malaria vaccine trial by the FDA. Also, they are making substantial investments in the UK, collaborating globally on oncology treatments, and resolving royalty disputes. The company's future, with BNT327's potential in
immunology therapy, looks bright despite a predicted revenue decline in 2025.
BIONTECH News Analytics from Sat, 28 Dec 2024 08:00:00 GMT to Sat, 07 Jun 2025 21:10:33 GMT -
